LARGE SCALE GENE DISCOVERY--HUMAN PROSTATE CANCER

描述：（改编自研究者摘要）EST（表达 序列标签）范例对表达的短片段进行随机测序 作为鉴定全长cDNA的手段， 由于缺乏技术创新， 关闭.该行业现在有数百万的EST，但无法扩展 这一发现过程的识别和表征 全长基因OriGene Technologies，Inc. (OTI)开发了两 允许高通量全长cDNA的互补技术 克隆。在这个快速的第一阶段-第二阶段申请中，OTI提出了一个基因， 针对人类前列腺癌的发现计划。在第一阶段组成部分中， 申请人提出生成高质量源材料， 支持II期阶段的大规模全长cDNA分离。三 具体目标如下：（1）建立正常前列腺cDNA文库 组织和前列腺腺癌，（2）排列来自每个组织的cDNA克隆， 文库到初级和次级多级板上，和（3）进行 对这些图书馆进行严格的质量控制。 前列腺癌是人类癌症中最常见的诊断形式， 美国的申请人声称许多在前列腺中发挥作用的基因 致癌作用可以作为有用的诊断工具和/或作为靶点， 治疗干预在第二阶段， 在第一阶段的组成部分将用于分离200全长cDNA 克隆，根据其前列腺特异性或前列腺 癌症特异性表达模式。申请人建议：（1）发展 选择可能在前列腺中发挥作用的重要EST的方法 （2）分离其相应的全长cDNA 从排列的cDNA文库板中克隆，和（3）确定5 ′ DNA 每一个序列，并确认其真实性。这个发现过程是 可能超出本申请中提出的工作范围。 拟议商业应用：不可用

DESCRIPTION: (Adapted from the investigator's abstract) The EST (expressed sequence tag) paradigm to randomly sequence short stretches of expressed regions of genes as a means to identify full-length cDNAs, has been challenged by the lack of technological innovations to pick up where this technology left off. The industry is now guttered with millions of ESTs but is unable to extend this discovery process to the identification and characterization of full-length genes. OriGene Technologies, Inc. (OTI) has developed two complementary technologies which allow high-throughput full-length cDNA cloning. In this fast-track Phase I - Phase II application, OTI proposes a gene discovery program that targets human prostate cancer. In the Phase I component, the applicants propose to generate high-quality source material which will support large-scale, full-length cDNA isolation at the Phase II stage. Three specific aims are proposed: (1) generating cDNA libraries from normal prostate tissue and prostatic adenocarcinomas, (2) arraying the cDNA clones from each library onto primary and secondary multi-level plates, and (3) performing stringent quality controls on these library. Prostate carcinoma is the most frequently diagnosed form of human cancer in the United States. The applicants assert that many genes which function in prostate carcinogenesis could serve as useful diagnostic tools and/or as targets for therapeutic intervention. In the Phase II component, source materials developed in the Phase I component will be used to isolate two hundred full-length cDNA clones, selected on the basis of their prostate-specific or prostate cancer-specific expression patterns. The applicants propose: (1) developing approaches to select important ESTs that potentially play a role in prostate growth and carcinogenesis, (2) isolating their corresponding full-length cDNA clones from the arrayed cDNA library panels, and (3) determining the 5' DNA sequence of each and confirming its authenticity. This discovery process is likely to extend beyond the work proposed in this application. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE